HuidaGene Therapeutics Gains FDA Clearance for First CRISPR/Cas13 RNA-Editing Therapy HG202 to Treat Macular Degeneration

Complete Genomics Unveils New Sequencing Innovations and Expanded DNBSEQ-T7 Applications at ASHG 2024

QIAGEN’s QIAstat-Dx Meningitis/Encephalitis Panel Gains FDA Clearance, Accelerating CNS Infection Diagnosis

Tempus AI to Acquire Ambry Genetics for $600 Million, Expanding Genetic Testing Capabilities

Aiforia and Paige form strategic partnership to advance AI integration in pathology laboratories

CytoDyn Receives FDA Clearance to Begin Phase II Trial of Leronlimab for Colorectal Cancer

MGM Medical College in Indore Pioneers CAR T Cell Therapy for Blood Cancer Treatment in India’s Public Healthcare System

AbbVie and EvolveImmune Therapeutics Partner in New Collaboration and Licensing Agreement to Advance Next-Generation Cancer Biotherapeutics

Cardiff Oncology Publishes Phase 2 Trial Data on Second-Line Treatment for KRAS-Mutant mCRC in *Journal of Clinical Oncology*

Advanced Genomics APAC and Compass Bioinformatics Forge Strategic Alliance to Enhance Rare Disease and Cancer Diagnostics in APAC Region

Telo Genomics Expands Mayo Clinic Collaboration to Advance Multiple Myeloma Prognostic Testing

Daiichi Sankyo and AstraZeneca Launch Phase 3 Trials of Datopotamab Deruxtecan-Based Combinations in Advanced Non-Small Cell Lung Cancer

FDA Approves Novartis Scemblix® for Newly Diagnosed CML, Showcasing Superior Efficacy and Improved Safety Profile

IDEAYA Biosciences Secures IND Clearance for IDE275 (GSK959) to Initiate Phase 1 Trial in MSI-High Solid Tumors

MGI Partners with OncoDNA to Enhance Precision Oncology with Compatible Genomic Solutions

Home
/
update
/
details

AbbVie and EvolveImmune Therapeutics Partner in New Collaboration and Licensing Agreement to Advance Next-Generation Cancer Biotherapeutics

NextEdge Admin

03 Nov 2024

2 min 17 sec

EvolveImmune Therapeutics,oncology,Partnership

AbbVie and EvolveImmune Therapeutics, a company focused on advancing immuno-oncology, have entered into a collaboration and option-to-license agreement aimed at developing multispecific biologics to target various types of cancer. This partnership will utilize EvolveImmune’s T-cell engager platform, EVOLVE, to create innovative antibody-based therapies for both solid and blood cancers.

The EVOLVE platform is designed to enhance the body’s immune response against tumors by delivering powerful and selective T-cell co-stimulation. This approach aims to overcome the common therapeutic obstacles, such as low tumor immunogenicity and T-cell dysfunction, which often limit the effectiveness of current immunotherapies in treating solid and hematologic cancers.

According to Jonathon Sedgwick, Ph.D., AbbVie’s senior vice president and global head of discovery research, this collaboration aligns with AbbVie’s commitment to advancing cancer treatments for patients with significant unmet needs. “We are excited to collaborate with the talented team at EvolveImmune to further advance their novel T-cell engager platform technology,” he noted.

Stephen Bloch, M.D., CEO of EvolveImmune, views the partnership as a significant endorsement of the EVOLVE platform, which uses a unique CD2 co-stimulation strategy to enhance T-cell engagement. "Our technology may offer clinically meaningful benefits for patients," Bloch stated.

Under the agreement, EvolveImmune will receive $65 million upfront in fees and equity investment, with the potential to earn up to $1.4 billion in option fees, milestone payments, and tiered royalties on future net sales.